Immunogenicity and safety of ChAdOx1 vaccine (Covid-19 vaccine) in Thai people with underlying disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20211228003

Enrollment

420

Registered

2021-12-28

Start date

2021-06-08

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus Cirrhosis solid cancer Hematologic malignancy chronic kidney disease rheumatological disease cardiovascular disease ChAdOx1 vaccine immunogenicity covid-19 vaccine

Interventions

ChAdOx1 vaccine, 2 doses, 12 weeks apart, intramuscular

Experimental Biological/Vaccine

ChAdOx1 vaccine

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. age more than 18 years old 2. Anti-SAR-CoV-2 negative 3. diabetes mellitus or 4. cirrhosis or 5. solid cancer or 6. hematologic malignancy or 7. chronic kidney disease (GFR <60 ml/mi/1.73 m2) 8. rheumatological disease or 9. cardiovascular disease

Exclusion criteria

Exclusion criteria: 1. previous covid-19 vaccination 2. prior other vaccine in 14 days 3. pregnancy 4. lactation

Design outcomes

Primary

Measure	Time frame
The change of geometric mean titer levels to RBD of spike protein compare 28 days and 180 days after 2 nd dose vaccination anti-Sar-Cov2	—

Secondary

Measure	Time frame
Immunogenicity response 56 days after 1st dose vaccination anti-Sar-Cov2,Immunogenicity response 90 days after 1st dose vaccination anti-Sar-Cov2,Immunogenicity response 28 days after 2nd dose vaccination anti-Sar-Cov2,Immunogenicity response 6 months after 2nd dose vaccination anti-Sar-Cov2	—

Countries

Thailand

Contacts

Public ContactKriangkrai Tawinprai

Chulabhorn Hospital

kriangkrai.taw@pccms.ac.th025766000

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026